American Homes 4 Rent Class A vs Regeneron Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.43 (market cap $11.97B), while Regeneron Pharmaceuticals Inc trades at $658.21 (market cap $69.67B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 5.8× American Homes 4 Rent Class A's market cap, and American Homes 4 Rent Class A pays the higher dividend (3.97%). Which is the better fit depends on your goals.
| AMH | REGN | |
|---|---|---|
Market Cap | $11.97B | $69.67B |
Sector | Real Estate | Health |
52-Week High | $36.74 | $812.27 |
52-Week Low | $27.38 | $542.52 |
Enterprise Value | $17.05B | $63.62B |
Dividend Yield | 3.97% | 0.57% |
Signals from Pluang's Aura AI — not financial advice
AMH (American Homes 4 Rent) trades at $33.27, up 1.0% with a bullish technical signal and strong earnings momentum after beating estimates for three consecutive quarters. The company maintains robust fundamentals with 24.48% net income margin and $1.85B revenue in 2025, supported by 95% occupancy rates in the single-family rental market. Recent dividend declaration of $0.33 per share and positive analyst sentiment with 58% buy ratings reinforce strength.
Outlook remains positive given consistent operational performance and strategic focus on Sunbelt and Midwest markets. Key risks include high debt levels at $5.01B and sensitivity to interest rate changes. With consensus price target of $35.68 offering 7.2% upside, the stock presents a compelling opportunity for income and growth investors despite macroeconomic headwinds.
Regeneron (REGN) trades at $664.52, down 0.54% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company maintains strong fundamentals with a P/E of 16.22, net income margin of 29.65%, and consistent earnings beats. Recent FDA acceptance for cemdisiran review and inclusion in a manufacturing facility pilot program highlight positive developments. Cash flow improved in 2025 with net cash flow of $634.70 million.
Outlook remains positive with a consensus price target of $764.50, implying 15% upside, supported by 69% analyst buy ratings. Risks include regulatory hurdles, competitive pressures, and dependence on key drug performance. The stock presents a compelling opportunity for growth investors given its valuation and pipeline progress, though near-term volatility may persist around earnings.
Trailing returns across standard periods
Latest headlines on both assets
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →